Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
- PMID: 9749478
- DOI: 10.1001/jama.280.11.969
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
Abstract
Context: Interstitial radiation (implant) therapy is used to treat clinically localized adenocarcinoma of the prostate, but how it compares with other treatments is not known.
Objective: To estimate control of prostate-specific antigen (PSA) after radical prostatectomy (RP), external beam radiation (RT), or implant with or without neoadjuvant androgen deprivation therapy in patients with clinically localized prostate cancer.
Design: Retrospective cohort study of outcome data compared using Cox regression multivariable analyses.
Setting and patients: A total of 1872 men treated between January 1989 and October 1997 with an RP (n = 888) or implant with or without neoadjuvant androgen deprivation therapy (n = 218) at the Hospital of the University of Pennsylvania, Philadelphia, or RT (n = 766) at the Joint Center for Radiation Therapy, Boston, Mass, were enrolled.
Main outcome measure: Actuarial freedom from PSA failure (defined as PSA outcome).
Results: The relative risk (RR) of PSA failure in low-risk patients (stage T1c, T2a and PSA level < or =10 ng/mL and Gleason score < or =6) treated using RT, implant plus androgen deprivation therapy, or implant therapy was 1.1 (95% confidence interval [CI], 0.5-2.7), 0.5 (95% CI, 0.1-1.9), and 1.1 (95% CI, 0.3-3.6), respectively, compared with those patients treated with RP. The RRs of PSA failure in the intermediate-risk patients (stage T2b or Gleason score of 7 or PSA level >10 and < or =20 ng/mL) and high-risk patients (stage T2c or PSA level >20 ng/mL or Gleason score > or =8) treated with implant compared with RP were 3.1 (95% CI, 1.5-6.1) and 3.0 (95% CI, 1.8-5.0), respectively. The addition of androgen deprivation to implant therapy did not improve PSA outcome in high-risk patients but resulted in a PSA outcome that was not statistically different compared with the results obtained using RP or RT in intermediate-risk patients. These results were unchanged when patients were stratified using the traditional rankings of biopsy Gleason scores of 2 through 4 vs 5 through 6 vs 7 vs 8 through 10.
Conclusions: Low-risk patients had estimates of 5-year PSA outcome after treatment with RP, RT, or implant with or without neoadjuvant androgen deprivation that were not statistically different, whereas intermediate- and high-risk patients treated with RP or RT did better then those treated by implant. Prospective randomized trials are needed to verify these findings.
Comment in
-
Comparing treatments for localized prostate cancer--persisting uncertainty.JAMA. 1998 Sep 16;280(11):1008-10. doi: 10.1001/jama.280.11.1008. JAMA. 1998. PMID: 9749485 No abstract available.
-
Prostatectomy, external beam radiation therapy, or brachytherapy for localized prostate cancer.JAMA. 1999 May 5;281(17):1583; author reply 1585-6. JAMA. 1999. PMID: 10235143 No abstract available.
-
Prostatectomy, external beam radiation therapy, or brachytherapy for localized prostate cancer.JAMA. 1999 May 5;281(17):1583-4; author reply 1585-6. JAMA. 1999. PMID: 10235144 No abstract available.
-
Prostatectomy, external beam radiation therapy, or brachytherapy for localized prostate cancer.JAMA. 1999 May 5;281(17):1584; author reply 1585-6. JAMA. 1999. PMID: 10235145 No abstract available.
-
Prostatectomy, external beam radiation therapy, or brachytherapy for localized prostate cancer.JAMA. 1999 May 5;281(17):1584-6. JAMA. 1999. PMID: 10235146 No abstract available.
Similar articles
-
Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.Cancer. 2002 Jul 15;95(2):281-6. doi: 10.1002/cncr.10657. Cancer. 2002. PMID: 12124827
-
Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):664-73. doi: 10.1016/s0360-3016(01)02670-0. Int J Radiat Oncol Biol Phys. 2002. PMID: 11849788
-
Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):645-53. doi: 10.1016/s0360-3016(03)00627-8. Int J Radiat Oncol Biol Phys. 2003. PMID: 14529768
-
Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.Brachytherapy. 2002;1(1):2-10. doi: 10.1016/s1538-4721(02)00006-5. Brachytherapy. 2002. PMID: 15062181 Review.
-
Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.Ann Intern Med. 2008 Mar 18;148(6):435-48. doi: 10.7326/0003-4819-148-6-200803180-00209. Epub 2008 Feb 4. Ann Intern Med. 2008. PMID: 18252677 Review.
Cited by
-
Interpreting Prostate MRI Reports in the Era of Increasing Prostate MRI Utilization: A Urologist's Perspective.Diagnostics (Basel). 2024 May 20;14(10):1060. doi: 10.3390/diagnostics14101060. Diagnostics (Basel). 2024. PMID: 38786358 Free PMC article. Review.
-
Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1.JU Open Plus. 2024 Apr;2(4):e00029. doi: 10.1097/ju9.0000000000000137. Epub 2024 Apr 15. JU Open Plus. 2024. PMID: 38774466 Free PMC article.
-
Cigarette smoking and prostate cancer aggressiveness among African and European American men.Cancer Causes Control. 2024 May 17. doi: 10.1007/s10552-024-01883-3. Online ahead of print. Cancer Causes Control. 2024. PMID: 38758522
-
A preoperative scoring system for predicting the extraprostatic extension of prostate cancer following radical prostatectomy using magnetic resonance imaging and clinical factors.Abdom Radiol (NY). 2024 May 16. doi: 10.1007/s00261-024-04345-1. Online ahead of print. Abdom Radiol (NY). 2024. PMID: 38755453
-
Differences in the expression of the phosphatase PTP-1B in patients with localized prostate cancer with and without adverse pathological features.Front Oncol. 2024 Apr 19;14:1334845. doi: 10.3389/fonc.2024.1334845. eCollection 2024. Front Oncol. 2024. PMID: 38706600 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous